Erythrodermic psoriasis treatment with Guselkumab: report of two cases and literature review
-
Published:2023-12
Issue:
Volume:
Page:
-
ISSN:0365-0596
-
Container-title:Anais Brasileiros de Dermatologia
-
language:en
-
Short-container-title:Anais Brasileiros de Dermatologia
Author:
Welsh EsperanzaORCID,
Cardenas-de la Garza Jesus AlbertoORCID,
García-Lozano José AlbertoORCID,
Flores-Gutierrez Diana PaolaORCID
Reference5 articles.
1. Treatment response of patients with erythrodermic psoriasis after switching to Guselkumab;Chiang;Dermatol Ther (Heidelb).,2021
2. A case of erythrodermic psoriasis successfully treated with guselkumab;Megna;Dermatol Ther.,2020
3. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study;Sano;J Dermatol.,2018
4. HHV8-Positive castleman disease and in situ mantle cell neoplasia within dermatopathic Lymphadenitis, in longstanding psoriasis;Zanelli;Diagnostics (Basel).,2021
5. Comparison of anti-TNF and IL-inhibitors treatments in patients with psoriasis in terms of response to routine laboratory parameter dynamics;Ataseven;J Dermatolog Treat.,2022